NanoViricides

Dr. Anil Diwan highlights the threat of rapidly evolving RNA viruses like H5N1, COVID-19, RSV, and hMPV, which can develop resistance to current treatments. NV-387, a broad-spectrum antiviral drug by NanoViricides, shows promise against these viruses by mimicking host features viruses need to infect, making viral escape unlikely. It has shown superior efficacy in animal models compared to existing treatments, positioning it as a potential game-changer in pandemic preparedness.

NanoViricides, Inc. is advancing NV-387, a broad-spectrum antiviral drug, into Phase II trials for treating viruses like RSV, COVID, and influenza. Its technology could revolutionize viral therapy, with potential applications against emerging threats like MPOX. The company is also exploring strategic agreements and updates on its clinical progress.

NanoViricides, Inc. claims NV-387, a broad-spectrum antiviral, is effective against H5N1 bird flu, as it mimics host-side features the virus relies on. NV-387 outperformed existing influenza drugs in animal studies and has completed Phase I human trials with no adverse events. The company is preparing Phase II trials for MPox and respiratory virus infections.

NanoViricides' NV-387, a broad-spectrum antiviral, could combat H5N1 bird flu as it mimics host-side features the virus uses despite mutations. In animal studies, NV-387 showed 88% increased survival vs. existing treatments. It completed Phase I trials with no adverse events and is preparing for Phase II trials for MPox and respiratory virus infections.

NanoViricides, Inc. claims its antiviral drug NV-387 is effective against H5N1 bird flu, as it mimics host features the virus needs, making escape unlikely. NV-387 has shown superior efficacy in animal studies and completed Phase I trials safely. The company is preparing for Phase II trials for MPox and respiratory viruses, positioning NV-387 as a key tool against potential pandemics.

Anil Diwan highlights the urgent need for effective treatments against H5N1 bird flu, emphasizing NanoViricides' NV-387 as a promising drug candidate. NV-387 outperforms existing therapies, targeting the virus's polybasic site, ensuring effectiveness despite mutations, unlike vaccines and antibodies that may lose potency.

Angela Harmantas, an Editor at Proactive with 15+ years in equity markets, focuses on junior resource stocks. Proactive provides global finance news, covering markets like biotech, mining, and crypto. They use technology to enhance workflows but maintain human-authored content.

NanoViricides reported Q3 2024 financials with $3.87M cash and $7.36M net property assets. Lead drug NV-387, a broad-spectrum antiviral, is advancing to Phase II trials for MPOX, RSV, Influenza, and COVID. A Phase Ia/Ib trial was completed with no adverse events. The company raised $1.71M through an ATM offering and has a $3M credit line, but additional funding is needed for planned Phase II trials. NV-387 showed promising results in animal trials, potentially offering superior effectiveness over existing treatments.

NanoViricides, Inc. reports progress on NV-387, a broad-spectrum antiviral drug moving toward Phase II trials for MPOX and RSV. The drug shows activity against COVID, RSV, Influenza, and MPOX/Smallpox. Financials reveal $3.87 million in cash assets and $1.63 million in liabilities as of September 30, 2024, with a funding shortfall for planned operations through November 2025.

NanoViricides, Inc. announces President & Exec. Chairman, Anil R. Diwan, Ph.D., will present a corporate update on the broad-spectrum antiviral drug candidate NV-387 at the Spartan Capital Investors Conference on Nov 4, 2024, in NYC. NV-387, developed using nanoviricides technology, has completed Phase I trials and shows strong antiviral activity against various diseases, targeting a market of over $10B by 2027.